MTA2在子宫内膜癌中的表达及其与临床病理特征的关系

Expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features

目的·探讨MTA2在子宫内膜癌中的表达及其与临床病理指标的相关性。方法·采用GCBI数据库分析MTA2在各肿瘤组织中的m RNA表达水平。采用免疫组织化学染色法检测MTA2、ER、PR、p53和Ki-67在119例子宫内膜癌组织和21例癌旁组织中的蛋白表达水平,并统计分析MTA2表达与子宫内膜癌临床病理特征的关系及与ER、PR、p53和Ki-67表达的相关性。结果·在GCBI数据库中,MTA2在包括子宫内膜癌在内的多数肿瘤中的表达均上调。MTA2在子宫内膜癌患者组织中的表达显著高于癌旁组织表达水平(P=0.000);MTA2的表达与肿瘤分级有关(χ~2=8.072,P=0.018);MTA2在子宫内膜癌中的表达与Ki-67的表达呈正相关(r=0.227,P=0.013),而与ER、PR和p53的表达无相关性。结论·MTA2在子宫内膜癌发生和发展的过程具有重要作用,预示MTA2具有成为诊断分子的潜能。

Objective To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features. Methods The GCBI database was used to analyse the MTA2 expression in most cancers, lmmunohistochemical staining of MTA2, p53, ER, PR and Ki- 67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria. And the correlation between MTA2 expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER, PR, p53 or Ki-67. Results The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCB1 database. MTA2 was overexpressed in endometrial carcinoma compared with the adjacent normal tissues （P=0.000）, and the expression level was related to tumor grade （χ^2=8.072, P=0.018） and Ki-67 expression （r=0.227, P-0.013）. Conclusion MTA2 may act as an oncogene in endometrial carcinomas, and it is a promising target for diagnosis and treatment of endometrial carcinomas.